CLINICAL_TRIALS
trial_result
· 2018-10-09
Clinical Trial Update: Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes [EARLY_Phase 1]
Summary
Early-phase trial evaluating modulating STAT3 signaling with siltuximab in Type 1 Diabetes completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Carla Greenbaum, MD | Conditions: Type 1 Diabetes | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2018-10-09